Showing results (121-130 of 301) with videos related to

Sort By:
Pageof 31
Current Drug Targets|December 8, 2004
Application of decoy oligodeoxynucleotides-based approach to renal diseasesNaruya Tomita, Haruhito Azuma, Yasufumi Kaneda, et al.
Current Drug Targets|April 18, 2003
Gene therapy with transcription factor decoy oligonucleotides as a potential treatment for cardiovascular diseasesNaruya Tomita, Haruhito Azuma, Yasufumi Kaneda, et al.
BMC Urology|June 8, 2004
Adult Wilms' tumor with calcification untreated for 5 years--a case reportHiroshi Masuda, Haruhito Azuma, Fumitaka Nakajima, et al.
Cardiovascular and Interventional Radiology|January 29, 2016
Novel Software-Assisted Hemodynamic Evaluation of Pelvic Flow During Chemoperfusion of Pelvic Arteries for Bladder Cancer: Double- Versus Single-Balloon TechniqueKiyohito Yamamoto, Kazuhiro Yamamoto, Go Nakai, et al.
Urologic Oncology|July 11, 2026
Efficacy and safety of first-line immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients on hemodialysisHidetsugu Takahashi, Wataru Fukuokaya, Takafumi Yanagisawa, et al.
NPJ Precision Oncology|September 17, 2024
Mechanistic insights into lethal hyper progressive disease induced by PD-L1 inhibitor in metastatic urothelial carcinomaKazuki Nishimura, Kiyoshi Takahara, Kazumasa Komura, et al.
Cancer|November 13, 2009
Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancerTeruo Inamoto, Bogdan A Czerniak, Colin P Dinney, et al.
Annals of Surgical Oncology|June 24, 2017
Preoperative Measurement of the Modified Glasgow Prognostic Score Predicts Patient Survival in Non-Metastatic Renal Cell Carcinoma Prior to NephrectomyTakuya Tsujino, Kazumasa Komura, Tomohisa Matsunaga, et al.
Cancer Diagnosis & Prognosis|May 11, 2023
Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial CarcinomaTeruo Inamoto, Ryo Sato, Yuto Matsushita, et al.
Annals of Surgical Oncology|June 27, 2019
The CANLPH Score, an Integrative Model of Systemic Inflammation and Nutrition Status (SINS), Predicts Clinical Outcomes After Surgery in Renal Cell Carcinoma: Data From a Multicenter Cohort in JapanKazumasa Komura, Takeshi Hashimoto, Takuya Tsujino, et al.
Pageof 31